A1M Pharma AB (publ) was formed in 2008 by researchers working at Lund University. Our drug candidate ROSgard™ is based on A1M (alpha-1-microglobulin), which is an endogenous protein that plays an important role in the body’s defence against oxidative stress. The main focus at present is on treatment of pre-eclampsia and acute kidney injury.
A1M Pharma has been listed on the stock exchange since 2013 and is listed on Nasdaq First North.
Key milestones
A1M Pharma has:
- successfully produced a recombinant version of A1M – a first so-called development batch – in order to more accurately evaluate the potential therapeutic effects
- developed a commercially applicable manufacturing process that has been scaled up from laboratory scale
- conducted extensive preclinical trials with promising results in a number of animal models for pre-eclampsia and kidney injury
- conducted supplementary studies in a human placental tissue model